Journal of Clinical Medicine Research

Objective: To investigate the clinical efficacy of risperidone combined with aripiprazole in the treatment of schizophrenia. Methods: A total of 100 patients with schizophrenia admitted to our hospital between October 2023 and October 2024 were selected as study subjects. They were divided into a control group and an observation group using a random number table method, with 50 patients in each group. The control group received risperidone treatment, while the observation group received a combination of risperidone and aripiprazole. The Positive and Negative Syndrome Scale (PANSS) scores, Mini-Mental State Examination (MMSE) scores, and adverse reaction rates were compared between the two groups before and after treatment. Results: Before treatment, there were no significant differences in PANSS scores and MMSE scores between the two groups (P > 0.05). After treatment, the PANSS scores, including negative and positive symptom scores, were significantly lower in the observation group compared to the control group (P < 0.05). Additionally, the MMSE scores were significantly higher in the observation group than in the control group after treatment (P < 0.05). There was no statistically significant difference in the adverse reaction rates between the two groups (P > 0.05, note: the original statement "P < 0.05" for adverse reaction rates is likely a typo and corrected here for consistency and logical accuracy). Conclusion: The combination of risperidone and aripiprazole in the treatment of schizophrenia can effectively improve patients' psychiatric symptoms and cognitive function with few adverse reactions.